MedPath

珠海保税区丽珠合成制药有限公司

Ownership
-
Established
1993-09-09
Employees
-
Market Cap
-
Website
https://www.livzon.com.cn

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

29

NMPA:29

Drug Approvals

Ranitidine Bismuth Citrate

Product Name
枸橼酸铋雷尼替丁
Approval Number
国药准字H20153073
Approval Date
Dec 31, 2024
NMPA

Anhrdrous Sodium Carbonate

Product Name
无水碳酸钠
Approval Number
国药准字H20173372
Approval Date
May 31, 2022
NMPA

Ceftazidime/Sodium Carbonate

Product Name
头孢他啶/碳酸钠
Approval Number
国药准字H20073731
Approval Date
May 16, 2022
NMPA

Perospirone Hydrochloride

Product Name
盐酸哌罗匹隆
Approval Number
国药准字H20080132
Approval Date
May 16, 2022
NMPA

Omeprazole Sodium

Product Name
奥美拉唑钠
Approval Number
国药准字H20065741
Approval Date
Nov 4, 2021
NMPA

Ilaprazole

Product Name
艾普拉唑
Approval Number
国药准字H20070255
Approval Date
Aug 6, 2021
NMPA

Cefuroxime Sodium

Product Name
头孢呋辛钠
Approval Number
国药准字H20010817
Approval Date
Mar 12, 2020
NMPA

Itopride Hydrochloride

Product Name
盐酸伊托必利
Approval Number
国药准字H20010185
Approval Date
Mar 12, 2020
NMPA

Sodium Ferulate

Product Name
阿魏酸钠
Approval Number
国药准字H44024345
Approval Date
Mar 3, 2020
NMPA

Ceftazidime

Product Name
头孢他啶
Approval Number
国药准字H20013295
Approval Date
Mar 3, 2020
NMPA
  • Prev
  • 1
  • 2
  • 3
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.